Dr. Lal PathLabs Limited

NSEI:LALPATHLAB 주식 보고서

시가총액: ₹254.4b

Dr. Lal PathLabs 과거 수익 실적

과거 기준 확인 5/6

Dr. Lal PathLabs은 연평균 8.1%의 비율로 수입이 증가해 온 반면, Healthcare 산업은 수입이 증가했으며, 연간 23.2%였습니다. 매출은 연평균 11.9%의 비율로 증가했습니다. Dr. Lal PathLabs의 자기자본이익률은 20%이고 순이익률은 17.1%입니다.

주요 정보

8.1%

수익 성장률

7.9%

EPS 성장률

Healthcare 산업 성장29.4%
매출 성장률11.9%
자기자본 수익률20.0%
순이익17.1%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

Recent updates

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

수익 및 비용 분석

Dr. Lal PathLabs 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NSEI:LALPATHLAB 수익, 비용 및 수입 (INR Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 2423,4644,0144,3120
30 Jun 2422,8753,8154,2270
31 Mar 2422,2663,5774,1350
31 Dec 2321,7223,2983,8560
30 Sep 2321,2273,0133,7720
30 Jun 2320,5522,6382,8690
31 Mar 2320,1692,3883,5770
31 Dec 2220,1142,4353,3490
30 Sep 2220,1892,4803,2990
30 Jun 2219,8352,7133,2550
31 Mar 2220,8743,4483,4800
31 Dec 2120,3293,6693,3030
30 Sep 2119,8844,0413,2640
30 Jun 2119,2193,9443,1260
31 Mar 2115,8132,9162,5010
31 Dec 2014,5202,4072,3430
30 Sep 2013,2752,0032,1600
30 Jun 2012,6121,9552,0790
31 Mar 2013,3042,2592,2220
31 Dec 1913,2982,4052,5400
30 Sep 1912,9442,3222,4930
30 Jun 1912,4632,0862,4120
31 Mar 1912,0341,9922,3410
31 Dec 1811,6911,9232,2940
30 Sep 1811,3931,8252,2380
30 Jun 1810,9991,7612,1730
31 Mar 1810,5691,7072,1020
31 Dec 1710,1001,6178980
30 Sep 179,5481,5658080
30 Jun 179,3891,5867520
31 Mar 179,1241,5461,6940
31 Dec 168,9021,5767000
30 Sep 168,7131,8766760
30 Jun 168,2491,4136250
31 Mar 167,9131,3225800
31 Dec 157,6541,2012,15211
31 Mar 156,5969084970
31 Mar 145,5797631,75510

양질의 수익: LALPATHLAB 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: LALPATHLAB 의 현재 순이익 이익률 (17.1%) 작년보다 높습니다 (14.2%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: LALPATHLAB 의 수입은 지난 5년 동안 매년 8.1% 씩 증가했습니다.

성장 가속화: 지난 1년간 LALPATHLAB 의 수익 증가율( 33.2% )은 연간 평균( 8.1% 초과합니다. ).

수익 대 산업: 지난 1년간 LALPATHLAB 수익 증가율( 33.2% )은 Healthcare 업계 33.2% 초과했습니다.


자기자본 수익률

높은 ROE: LALPATHLAB 의 자본 수익률( 20% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기